Pulmonary sarcoidosis
ERS Monograph
; 2022(96):122-141, 2022.
Article
in English
| EMBASE | ID: covidwho-2315675
ABSTRACT
The lung is the most common organ affected by sarcoidosis. Multiple tools are available to assist clinicians in assessing lung disease activity and in excluding alternative causes of respiratory symptoms. Improving outcomes in pulmonary sarcoidosis should focus on preventing disease progression and disability, and preserving quality of life, in addition to timely identification and management of complications like fibrotic pulmonary sarcoidosis. While steroids continue to be first-line therapy, other therapies with fewer long-term side-effects are available and should be considered in certain circumstances. Knowledge of common clinical features of pulmonary sarcoidosis and specific pulmonary sarcoidosis phenotypes is important for identifying patients who are more likely to benefit from treatment.Copyright © ERS 2022.
apoptosis; arterial embolization; article; aspergillosis; asthma; bronchiectasis; bronchoscopy; cardiopulmonary exercise test; cause of death; chylothorax; computer assisted tomography; coughing; cystic fibrosis; depression; disability; disease exacerbation; disease severity; dysphagia; dyspnea; echocardiography; endobronchial ultrasonography; eosinophilia; fatigue; fever; fibrosing alveolitis; forced expiratory volume; forced vital capacity; graft survival; granulomatous inflammation; health care utilization; heart failure; hematothorax; human; immunosuppressive treatment; interstitial pneumonia; kidney biopsy; leukocyte differential count; lung biopsy; lung clearance; lung disease; lung function test; lung sarcoidosis; lung transplantation; lung vascular resistance; mediastinoscopy; muscle weakness; mycetoma; night sweat; oxygen consumption; oxygen desaturation; physical activity; pleura effusion; prevalence; pulmonary hypertension; pulmonary rehabilitation; quality of life; resistance training; respiratory failure; risk factor; Severe acute respiratory syndrome coronavirus 2; spirometry; stenosis; thorax pain; thorax radiography; total lung capacity; tuberculosis; wheezing; amphotericin B; azathioprine; corticosteroid; fluconazole; immunoglobulin E; infliximab; interleukin 2 receptor; itraconazole; methacholine; methotrexate; methylprednisolone; mycophenolate mofetil; pirfenidone; prednisolone; prednisone; pyrazinamide; rituximab; tacrolimus; voriconazole
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
ERS Monograph
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS